Scan run #1

Started 28-apr-2026 13:36 · finished 28-apr-2026 14:46 · triggered by cron

Items fetched	Relevant	Stored	New pages
172	105	105	92

New pages this run

The "92" New pages column above counts new wiki pages created across every area (the column name new_mechanisms is a v1 holdover — it covers mechanisms + treatments + subtypes + transplant-timing + symptoms + lifestyle).

Area	Page	Mentions to date
Lifestyle & Environmental Factors	Curcumin Supplementation	1
Lifestyle & Environmental Factors	N-Acetylcysteine Supplementation	1
Mechanisms & Pathways	ACVR1 signaling and hepcidin axis	19
Mechanisms & Pathways	CCR2 monocyte trafficking in MPN fibrosis	6
Mechanisms & Pathways	CSF-1R signaling and macrophage axis in MPN	1
Mechanisms & Pathways	Cytokine-induced memory-like (CIML) NK cells in myeloid malignancies	5
Mechanisms & Pathways	ERK/MAPK signaling in MPN	6
Mechanisms & Pathways	IRAK1/NF-κB signaling in MPN	1
Mechanisms & Pathways	Interferon-α mechanism of action in MPN	20
Mechanisms & Pathways	PD-1/PD-L1 immune checkpoint signaling in MPN	9
Mechanisms & Pathways	PLK1 (Polo-like kinase 1) signaling in MPN/CMML	1
Mechanisms & Pathways	RSK1 (Ribosomal S6 Kinase 1) signaling in myelofibrosis	1
Mechanisms & Pathways	S100A9 alarmin signaling	4
Mechanisms & Pathways	TGF-β superfamily signaling in MPN	13
Stem Cell Transplant Decisions	Accelerated/blast phase MPN pre-transplant bridging	14
Stem Cell Transplant Decisions	CIML NK cell therapy for post-transplant MPN relapse	3
Stem Cell Transplant Decisions	Conditioning regimen comparison: FluBu vs FluBu+TBI in myeloid malignancies	6
Stem Cell Transplant Decisions	Gecacitinib (JAK/ACVR1 inhibitor) for aGVHD prophylaxis	2
Stem Cell Transplant Decisions	Itacitinib (JAK1-selective) for GVHD prophylaxis	2
Stem Cell Transplant Decisions	Peri-transplant momelotinib in myelofibrosis	1
Stem Cell Transplant Decisions	Post-transplant HMA maintenance (oral decitabine/cedazuridine)	4
Stem Cell Transplant Decisions	Post-transplant erythroid engraftment in myelofibrosis	3
Stem Cell Transplant Decisions	T-cell depleted, immunoregulatory-enriched grafts with RIC	2
Treatments	ASTX029 (ERK inhibitor)	1
Treatments	Accelerated/blast phase MPN pre-transplant bridging	1
Treatments	Axatilimab (anti-CSF-1R antibody for advanced MPN/CMML)	1
Treatments	Azacitidine + Quizartinib combination	1
Treatments	Azacitidine + Venetoclax + Gilteritinib combination	7
Treatments	Azacitidine + Venetoclax combination (higher-risk CMML)	1
Treatments	BGB-11417 (BCL-2 inhibitor for myeloid malignancies)	1
Treatments	CER-1236 (novel investigational agent for AML/MDS/MF)	1
Treatments	CIML NK Cell Infusion + IL-2 (post-transplant relapse)	1
Treatments	CPX-351 (VYXEOS) for secondary myeloid neoplasms (pediatric/young adult)	1
Treatments	CPX-351 (liposomal daunorubicin + cytarabine)	2
Treatments	Canakinumab (IL-1β monoclonal antibody)	1
Treatments	Canakinumab (anti-IL-1β monoclonal antibody) for MDS/CMML	1
Treatments	Curcumin (C3 complex/Bioperine)	1
Treatments	DISC-0974 (anemia-targeting agent for MF/MDS)	1
Treatments	DISC-3405 (novel agent for Polycythemia Vera)	1
Treatments	Direct Oral Anticoagulants (DOACs) for MPN thromboprophylaxis	1
Treatments	Elritercept (novel agent for myelofibrosis)	5
Treatments	Fedratinib + Nivolumab combination	1
Treatments	Flonoltinib Maleate (JAK inhibitor)	1
Treatments	Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis)	1
Treatments	Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis)	1
Treatments	Fludarabine + Busulfan + Low-dose TBI conditioning regimen	1
Treatments	Fludarabine + Busulfan conditioning regimen	8
Treatments	Gecacitinib (JAK inhibitor)	1
Treatments	Gecacitinib hydrochloride (JAK/ACVR1 inhibitor)	2
Treatments	Givinostat (HDAC inhibitor)	1
Treatments	Guadecitabine + Atezolizumab combination	1
Treatments	INCA033989 (novel investigational agent for MPN)	20
Treatments	INCA035784 (novel investigational agent for MPN)	1
Treatments	INCA036978 (novel investigational agent for MPN)	1
Treatments	INCB057643 (BET bromodomain inhibitor)	7
Treatments	INCB160058 (novel investigational agent for MPN)	1
Treatments	IOA-244 (PI3Kδ inhibitor)	1
Treatments	Itacitinib + Tacrolimus + Sirolimus (GVHD prophylaxis)	3
Treatments	JNJ-88549968 (novel investigational agent for CALR-mutated MPN)	1
Treatments	Luspatercept	1
Treatments	Luspatercept (post-transplant erythroid engraftment)	1
Treatments	MEX-CD1 extracorporeal iron chelation device	1
Treatments	N-Acetylcysteine (NAC) for MPN	1
Treatments	NC525 (novel investigational agent for advanced myeloid neoplasms)	1
Treatments	NMS-03592088 (novel investigational agent for AML/CMML)	1
Treatments	Navitoclax + Ruxolitinib combination	2
Treatments	Navitoclax + Venetoclax + Decitabine combination	8
Treatments	Nelfinavir (repurposed for myelofibrosis anemia)	1
Treatments	Nuvisertib (TP-3654) (PIM kinase inhibitor for myelofibrosis)	1
Treatments	Olutasidenib (IDH1 inhibitor, post-transplant maintenance)	1
Treatments	Onvansertib (PLK1 inhibitor) for CMML/MDS-MPN overlap	1
Treatments	PMD-026 (RSK1 inhibitor)	1
Treatments	PRT12396	1
Treatments	Peginterferon alfa-2a (Pegasys)	1
Treatments	Peri-transplant ruxolitinib for GVHD prevention	6
Treatments	Pre-transplant bridging (ruxolitinib)	11
Treatments	Ropeginterferon alfa-2b + Ruxolitinib combination (myelofibrosis)	1
Treatments	Ruxolitinib + Azacytidine combination	1
Treatments	Ruxolitinib + Panobinostat combination	1
Treatments	Ruxolitinib + Thalidomide combination	1
Treatments	Ruxolitinib + Ulixertinib combination	1
Treatments	STP938 (novel investigational agent for Essential Thrombocythemia)	1
Treatments	STX-0712 (novel investigational agent for CMML/AML)	1
Treatments	Sapablursen (TMPRSS6 inhibitor / hepcidin-axis RNA interference)	1
Treatments	Seclidemstat + Azacitidine combination (MDS/CMML)	1
Treatments	Selinexor + Pacritinib combination	1
Treatments	Selinexor monotherapy (JAKi-naïve myelofibrosis)	1
Treatments	TQ05105 (novel JAK inhibitor for myelofibrosis)	1
Treatments	Tasquinimod (S100A9/HDAC4 inhibitor)	1
Treatments	Topotecan + Carboplatin + Veliparib	1
Treatments	WJ01024 + Ruxolitinib combination	1
Treatments	ZE74-0282 (novel JAK2 V617F-targeting agent)	1

Dynamic queries this run

SPEC-V2.4 — the expander proposes new searches for pages that have crossed their mention threshold. They run on subsequent scans alongside the static spec queries.

Metric	Count
New queries proposed	0
Active queries that fired	0
Items pulled in via dynamic queries	0
Queries auto-demoted this run	0